Exact Sciences improves its colon cancer screening technology

By Ted A. Knutson

Washington, Jan. 10 - Exact Sciences Corp. announced Tuesday that improvements to its technology demonstrated sensitivity in excess of 80% for detecting colorectal cancer in a recent research study.

The blinded study was designed to test the efficacy of technological advances to enhance colorectal cancer detection in stool. The study results have been submitted for presentation at the upcoming annual meeting of gastroenterologists, Digestive Disease Week, which will be held in May. The results are also being submitted for publication.

"I believe these research results validate the importance and promise of stool-based cancer detection and, over time, will lead to both improved colorectal cancer detection rates and reduced assay costs," commented Don Hardison, Exact Sciences' president and chief executive officer, in a news release.

Marlborough, Mass.-based Exact Sciences uses applied genomics to develop screening technologies for use in the detection of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.